Mirtazapine Is More Sedating Than Trazodone
Mirtazapine produces greater acute sedation than trazodone, particularly at lower doses (7.5–15 mg), due to its potent histamine H1 receptor antagonism, though both drugs demonstrate comparable sedative efficacy for chronic insomnia treatment at therapeutic doses. 1
Comparative Sedation Profile
Acute Sedation Effects
Mirtazapine causes significantly greater daytime sleepiness and impaired driving performance (increased standard deviation of lateral position) compared to trazodone on Day 2 of treatment, with mirtazapine also producing higher Stanford Sleepiness Scale scores than both trazodone and placebo 1.
The sedative effects of mirtazapine are dose-dependent and paradoxically stronger at lower doses (7.5–15 mg) due to unopposed H1 antagonism; at higher doses (≥30 mg), increased noradrenergic activity partially counteracts sedation 2, 3, 4.
Trazodone's sedation at low doses (25–75 mg) results primarily from 5-HT2A receptor antagonism (Ki = 35.6 nM), H1 receptor antagonism, and alpha-1 adrenergic blockade, producing less pronounced acute impairment than mirtazapine 5, 3, 6.
Tolerance Development
Mirtazapine's sedative effects substantially diminish with repeated administration; by Day 9 of continuous dosing, driving impairment and sleepiness resolved to baseline levels 1.
Trazodone did not significantly affect driving performance or cognitive function under either acute or repeated administration in healthy volunteers, suggesting less initial sedation liability 1.
Clinical Efficacy for Insomnia
Long-Term Treatment Outcomes
Both medications demonstrated equivalent efficacy for chronic insomnia over ≥3 months, with response rates of 87.87% for trazodone versus 86.95% for mirtazapine (p=0.26), regardless of sex, age, or comorbid dysthymia 7.
Maximum efficacy occurred at minimum doses: 25 mg trazodone (37.93% of responders) and 7.5 mg mirtazapine (52.5% of responders), with significantly lower response rates at higher doses (100–150 mg trazodone: 42.85%; 15–30 mg mirtazapine: 53.84%) 7.
Both medications maintained sustained efficacy without evidence of tolerance development over long-term treatment 7.
Guideline Positioning
The 2008 American Academy of Sleep Medicine guideline lists both trazodone and mirtazapine as third-line sedating antidepressants for chronic insomnia, recommended only after benzodiazepine receptor agonists or ramelteon have failed, or when treating comorbid depression/anxiety 8.
The 2020 VA/DoD guideline strongly recommends against trazodone for primary chronic insomnia due to lack of objective sleep improvement (no significant differences in sleep efficiency, onset latency, or total sleep time versus placebo) and unfavorable adverse-effect profile 9.
Neither medication is FDA-approved for insomnia; both represent off-label use with relatively weak efficacy evidence compared to approved hypnotics 8, 9.
Safety and Tolerability Considerations
Adverse Effect Profile
Mirtazapine's most common adverse effects are somnolence (≈23%), increased appetite, weight gain, and dizziness; elderly patients face increased risk of falls, cognitive impairment, and hyponatremia 2, 3, 4.
Trazodone carries higher discontinuation rates due to adverse effects (Risk Ratio = 2.30), higher overall adverse-effect rates (RR = 1.18), and markedly higher sleep-related adverse effects (RR = 4.31) compared to placebo 9.
Common trazodone adverse events include daytime drowsiness (≥20%), decreased appetite, headache (≈30%), with elderly patients at increased risk for falls and hyponatremia (serum sodium <110 mmol/L reported) 9.
Comparative Safety in Older Adults
In older adults (≥65 years), low-dose quetiapine for insomnia showed significantly higher mortality, dementia, and fall rates compared to trazodone, and higher dementia rates compared to mirtazapine, suggesting both sedating antidepressants are safer alternatives to antipsychotics 10.
Mirtazapine clearance is reduced in elderly patients and those with moderate-to-severe renal or hepatic impairment, requiring dose reduction and conservative starting doses 2.
Practical Prescribing Algorithm
When Sedation Is the Primary Goal
For acute sedation needs (e.g., severe insomnia with agitation): Start mirtazapine 7.5–15 mg at bedtime; expect maximal sedation within 1–2 hours, with tolerance developing over 7–10 days 2, 1, 4.
For sustained sedation without tolerance: Start trazodone 25–50 mg one hour before bedtime with food; titrate to 50–75 mg if needed, avoiding doses >100 mg to prevent reduced efficacy 9, 5, 7.
Monitor for next-day impairment: Mirtazapine requires assessment of driving safety and cognitive function during the first week; trazodone poses lower acute impairment risk 1.
When Treating Comorbid Depression
For depression with insomnia and anxiety: Mirtazapine 15–45 mg provides dual benefit through enhanced noradrenergic and serotonergic neurotransmission, with antidepressant effects emerging at 1–2 weeks 3, 4.
For depression with insomnia but concern for weight gain: Trazodone 150–300 mg (divided doses) offers antidepressant efficacy with less weight gain than mirtazapine, though sexual dysfunction risk is lower with both compared to SSRIs 11, 3, 6.
Critical Caveats
Neither medication should be first-line for primary chronic insomnia; cognitive-behavioral therapy for insomnia (CBT-I) remains the recommended initial treatment, with benzodiazepine receptor agonists preferred when pharmacotherapy is necessary 8, 9.
Trazodone's lack of objective sleep improvement in controlled trials (mean improvements: 10 min shorter latency, 22 min longer total sleep time, 8 min less wake after sleep onset—all below clinically significant thresholds) limits its evidence base despite widespread off-label use 9.
Both medications require informed consent regarding off-label use, screening for contraindications (cardiac disease, priapism risk for trazodone; seizure history for mirtazapine), and review of drug interactions, particularly with other serotonergic agents 9, 2, 5.
Paradoxically, higher doses of both medications may reduce sedative efficacy for insomnia while increasing adverse effects; maintain lowest effective dose 7.